Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04263909 · ClinicalTrials.gov registry record · Phase 4

The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients

A Phase 4 study, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 4
Development phase
199
Enrollment target

NCT04263909 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 199 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04263909, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 4
Development phase
199 participants
Enrollment target

Study Summary

In this study the investigators plan to examine the perioperative use of sufentanil sublingual (SL) in the analgesic regimen for spine surgery, one of the most common surgeries performed in the US. Patients undergoing spinal fusion surgery often experience severe pain during the first three postoperative days. Currently, no data are available for this patient population which routinely experiences moderate to severe acute pain. The investigators will analyze whether sufentanil SL is associated with lower opioid consumption in the post anesthesia care unit and pain scores.

Interventions

  • DRUG Sublingual Tablet

Trial Details

FieldValue
Enrollment Target 199 participants
Start Date 2020-12-01
Est. Completion 2023-12-30
Phase Phase 4

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT04263909

The ClinicalTrials.gov registry entry for NCT04263909 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Sublingual Tablet is the first listed.

NCT04263909 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04263909 about?

NCT04263909 is a clinical study titled "The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients". In this study the investigators plan to examine the perioperative use of sufentanil sublingual (SL) in the analgesic regimen for spine surgery, one of the most common surgeries performed in the US. Patients undergoing spinal fusion surgery often experience severe pain during the first three postoper...

What is the current status of trial NCT04263909?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 199 participants. The study started on 2020-12-01. Estimated completion is 2023-12-30.

What interventions are being tested in trial NCT04263909?

The interventions under investigation include: Sublingual Tablet (DRUG).

Who is sponsoring clinical trial NCT04263909?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.